Experimental drugs to lower Lp(a) move toward market, promising billions in potential sales
read at STAT ↗Positive
High levels of lipoprotein(a), or Lp(a), are a genetic risk factor for heart disease that affects roughly one in five people and currently has no approved therapy.
Several drugmakers are moving experimental treatments into late-stage trials, with Novartis highlighted as a front-runner in the race.
Industry observers estimate the market could be worth billions of dollars if a safe and effective drug receives regulatory approval.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: New treatments for common cardiovascular risk factor near the market, with billions at stake”
read at STAT ↗430 words · retrieved Aug 26
comments(0)
5-min edit window · permanent after that